

**1058. Decreases in Antibiotic Use Associated with the Implementation of Electronic Antibiotic Visualization Tools for Stewards at Eight Veterans Affairs (VA) Healthcare Facilities**

Christopher J. Graber, MD, MPH<sup>1</sup>; Makoto M. Jones, MD<sup>2</sup>; Matthew B. Goetz, MD<sup>3</sup>; Karl Madaras-Kelly, PharmD, MPH<sup>4</sup>; Yue Zhang, PhD<sup>5</sup>; Jorie M. Butler, PhD<sup>5</sup>; Charlene Weir, PhD, RN<sup>5</sup>; Ann F. Chou, PhD<sup>6</sup>; Sarah Y. Youn<sup>7</sup>; Matthew H. Samore, MD<sup>5</sup>; Peter A. Glassman, MBBS<sup>1</sup>; <sup>1</sup>VA Greater Los Angeles Healthcare System/University of California at Los Angeles, Los Angeles, California; <sup>2</sup>IDEAS Center of Innovation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah; <sup>3</sup>VA Greater Los Angeles Healthcare System and David Geffen School of Medicine, University of California at Los Angeles, VA-CDC Practice-Based Research Network, Los Angeles, California; <sup>4</sup>Idaho State University, Pocatello, Idaho; <sup>5</sup>University of Utah, Salt Lake City, Utah; <sup>6</sup>Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma; <sup>7</sup>VA Greater Los Angeles Healthcare System, Los Angeles, California

**Session:** 131. Antibiotic Stewardship: Interventions




Friday, October 4, 2019: 12:15 PM

**Background.** To identify areas for improved antibiotic use, we developed and pilot-tested visualization tools to quantify antibiotic use at 8 VA facilities. These tools allow a facility to review its patterns of total use, and use by antibiotic class, compared with patterns of use at VA facilities with similar (or user-selected) complexity levels.

**Methods.** Antibiotic stewards from 8 VA facilities participated in iterative report development and implementation, with the final product consisting of two components: an interactive web-based antibiotic dashboard and a standardized antibiotic usage report updated at user-selected intervals. Stewards also participated in monthly learning collaboratives. The percent change in average monthly antimicrobial use (all antibiotics; anti-methicillin-resistant *S. aureus* agents (anti-MRSA); and broad-spectrum agents predominantly used for hospital-onset/multi-drug-resistant organisms (anti-MDRO)) was analyzed using a pre-post (January 2014–January 2016 vs. July 2016–January 2018) with un-involved controls (all other inpatient VA facilities,  $n = 132$ ) design modeled using Generalized Estimation Equations segmented regression.

**Results.** Intervention sites had a 2.1% decrease (95% CI = [-5.7%,1.6%]) in all antibiotic use pre-post-intervention, vs. a 2.5% increase (95% CI = [0.8%, 4.1%]) in nonintervention sites ( $P = 0.025$  for difference). Anti-MRSA antibiotic use decreased 11.3% (95% CI = [-16.0%, -6.3%]) at intervention sites vs. a 6.6% decrease (95% CI = [-9.1%, -3.9%]) at nonintervention sites ( $P = 0.092$  for difference). Anti-MDRO antibiotic use decreased 3.4% (95% CI = [-8.2%, 1.7%]) at intervention sites vs. a 3.6% increase (95% CI = [0.8%, 6.5%]) at nonintervention sites ( $P = 0.018$  for difference) (Figure 1). Examples of graphs include overall antibacterial use (Figure 2), and usage of broad-spectrum Gram-negative therapy (Figure 3) in intensive care units.

**Conclusion.** The use of data visualization tools use and participation in monthly learning collaboratives by antimicrobial stewards in a pilot implementation project at eight VA facilities was associated with decreases in antimicrobial use relative to uninvolved sites.



**Disclosures.** All authors: No reported disclosures.

**1059. Impact of a Syndrome-Based Antimicrobial Stewardship Intervention on Anti-Pseudomonal β-Lactam Use, *C. difficile* Rates and Cost in an Urban Community Hospital**

Alfredo J. Mena Lora, MD<sup>1</sup>; Martin Cortez, PharmD<sup>2</sup>; Ella Li, PharmD<sup>2</sup>; Lawrence Sanchez, PharmD<sup>2</sup>; Rochelle Bello, MSN PhD<sup>2</sup>; Candice Krill, RN MBA<sup>2</sup>; Yolanda Coleman, RN PhD<sup>2</sup>; Eden Takhs, MD<sup>2</sup>; Susan C. Bleasdale, MD<sup>1</sup>; <sup>1</sup>University of Illinois at Chicago, Chicago, Illinois; <sup>2</sup>Saint Anthony Hospital, Chicago, Illinois

**Session:** 131. Antibiotic Stewardship: Interventions

Friday, October 4, 2019: 12:15 PM

**Background.** The use of anti-Pseudomonal β-lactam (APBL) agents has significantly increased in the past decade, carrying higher costs and contributing to antimicrobial pressure. Antimicrobial stewardship (ASP) can promote evidence-based antimicrobial selection and mitigate excess APBL use. We implemented a comprehensive ASP with syndrome-based prospective audit and feedback (PAF) at an urban community hospital. The goal of this study is to assess the impact of syndrome-based PAF on APBL use, *C. difficile* rates and cost.

**Methods.** ASP with all CDC core elements was implemented at a 151-bed community hospital in October 2017. Syndrome-based guidelines and PAF was established and overseen via direct communication with an ID physician. Days of therapy (DOT), cost and *C. difficile* rates were assessed 12 months before and after ASP. DOT for APBL and non-APBL utilization was tabulated by unit and paired t-test performed.

**Results.** Most cases reviewed by PAF (51%) were represented in our syndrome-based treatment guidelines (Figure 1). Soft tissue (33%) and intra-abdominal (24%) infections were the most common syndromes. Change to guideline was the most common PAF intervention (62%) followed by de-escalation (30%). At 12 months, total DOT/1,000 increased (392.5 vs. 404) while the proportion of parenteral antimicrobials used decreased (71% vs. 65%). Antibiotic expenditures decreased by 23%, with a reduction in APBL of 20% and non-APBL of 10% (Table 1). Statistically significant reductions APBL use in non-ICU settings ( $P = 0.0139$ ) and statistically significant increases in non-APBL in ICU settings occurred ( $P = 0.0001$ ) (Figure 2 and 3). *C. difficile* rates decreased from 21% (3.27 vs. 2.56).

**Conclusion.** Syndrome-based PAF was successfully implemented. A reduction in APBL use was seen in non-ICU settings, where evidence-based de-escalation may be more feasible. APBL use remained high in the ICU but was guideline consistent. A rise in non-APBL use also occurred. Certain critical illness syndromes warrant APBLs, but PAF may promote culture-directed and syndrome-specific treatments. ASP increased guideline-based therapy and contributed to decreased broad-spectrum antimicrobial use, antimicrobial expenditures and *C. difficile* rates. Syndrome based PAF can be successfully implemented in community settings.

	Before	After
Antibacterial expenditures	\$172,897	\$132,053
APBL expenditures	\$31674	\$25389
Non-APBL expenditures	\$60267	\$54416

Figure 1. Cases reviewed by syndrome-based prospective audit and feedback

